cardiac failure

A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone.&nbsp; However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>

ESC 2022

ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with a higher risk of dementia than the general population.&nbsp; A component of sacubitril/valsartan inhibits neprilysin—an enzyme involved in amyloid-β peptide degradation (Alzheimer’s disease)—, and that could worsen cognitive impairment. The PERSPECTIVE study is the first randomized trial to<a href="https://solaci.org/en/2022/08/30/esc-2022-perspective-efficacy-and-safety-of-sacubitril-valsartan-compared-with-valsartan-in-cognitive-function-of-patients-with-cardiac-failure-and-preserved-function/" title="Read more" >...</a>

ticagrelor vs. aspirina

Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction

Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the<a href="https://solaci.org/en/2021/12/13/empagliflozin-better-quality-of-life-for-patients-with-cardiac-failure-and-preserved-ejection-fraction/" title="Read more" >...</a>

Historia natural de la infección asintomática por COVID-19

New Cardiac Failure Diagnoses after COVID-19 Infection

This is the largest study on new signs and symptoms of cardiac failure in patients after COVID-19. Even though low in prevalence, its occurrence in healthy patients with no prior risk factors is worrying.&nbsp; The potential for SARS-CoV 2 to directly affect the heart has been studied since the pandemic onset. These studies have shown<a href="https://solaci.org/en/2021/05/05/new-cardiac-failure-diagnoses-after-covid-19-infection/" title="Read more" >...</a>

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents

The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior MI and hypersensitivity C-reactive protein (hsCRP) showed dose dependent hospitalization reduction for cardiac failure with the new anti-inflammatory drug Canakinumab, according to this study presented at AHA and simultaneously published in Circulation.   The difference between Canakinumab and<a href="https://solaci.org/en/2018/11/27/aha-2018-canakinumab-reduces-hospitalization-for-cardiac-failure-in-respondents/" title="Read more" >...</a>

AHA 2020 | EMPATROPISM: Empagliflozina en no diabéticos con insuficiencia cardíaca

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction.&nbsp; These findings were presented during the scientific sessions at AHA 2020 and published simultaneously in JACC. EMPATROPISM outcomes are on the same line as other studies using sodium glucose 2 cotransporter inhibitors (SGLT2) which showed<a href="https://solaci.org/en/2020/11/23/aha-2020-empatropism-empagliflozin-in-non-diabetics-with-cardiac-failure/" title="Read more" >...</a>

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | AFFIRM-AHF: Ferric Carboxymaltose and Fewer Hospitalizations for Cardiac Failure

Correcting iron deficiency in patients with cardiac failure might reduce the risk of new hospitalizations according to the AFFIRM-AHF published in the Lancet and presented at AHA 2020. The combined primary end point of death and hospitalizations was not met; yet the study showed a significant reduction of 26% in hospitalization rate. Irrespective of the<a href="https://solaci.org/en/2020/11/18/aha-2020-affirm-ahf-ferric-carboxymaltose-and-fewer-hospitalizations-for-cardiac-failure/" title="Read more" >...</a>

ACC 2020 Virtual | Vericiguat: una nueva esperanza en insuficiencia cardíaca crónica

Virtual ACC 2020 | Vericiguat: New Hope in Chronic Cardiac Failure

Treatment with the new drug called Vericiguat (acting on guanosine monophosphate receptors GMP) might reduce cardiovascular mortality or hospitalizations due to heart failure in a high-risk population with reduced ejection fraction.&nbsp; The VICTORIA trial (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) was presented virtually at the ACC 2020 scientific sessions<a href="https://solaci.org/en/2020/04/01/virtual-acc-202-vericiguat-new-hope-in-chronic-cardiac-failure/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Mitral Valve Repair in Patients with Cardiac Failure

The mitral valve is a complex apparatus dependent on left atrium and left ventricle functionality. Dilation of these cavities might affect mitral annulus morphology and lead to valve dysfunction, generating mitral regurgitation (MR). This type of MR has been called functional, since leaflets and tendinous chordae do not present lesions themselves; instead, they malfunction ‘secondary’<a href="https://solaci.org/en/2018/10/01/mitral-valve-repair-in-patients-with-cardiac-failure/" title="Read more" >...</a>

Resonancia vs FFR en lesiones no culpables del infarto

Cardiac Angiography: Necessary for CABG Patient Diagnosis?

Cardiac revascularization surgery (CABG) has shown positive results at long term in CAD patients with multivessel or left main disease. However, we are well aware that, after CABG, there might be native disease progression over time. Also, at followup, we often see high incidence of venous graft failure.&nbsp; According to registry data, approximately 1 in<a href="https://solaci.org/en/2023/10/12/cardiac-angiography-necessary-for-cabg-patient-diagnosis/" title="Read more" >...</a>

Top